Calgary-based Resverlogix announced the addition of Professor H. Bryan Brewer to Resverlogix's Clinical Steering Committee.
Brewer, a cardiologist, is currently Director of Lipoprotein and Atherosclerosis Research, Cardiovascular Research Institute, Washington Hospital Center, Washington, D.C. He was the former chief of the Molecular Disease Branch at the National Institute of Health, Bethesda, Md., and is a leader and pioneer in the field of high density lipoprotein (HDL) research. His seminal observations led to the cloning of the Apolipoprotein A-I (ApoA-I) mRNA and the gene.
The availability of the ApoA-I mRNA and the gene enabled clinicians and scientists to understand the role of ApoA-I protein in reverse cholesterol transport (RCT) and atherosclerosis protection.
"Professor Brewer is one of the most well-respected pioneers in the field of HDL biology. He has extensive industry expertise having served as a consultant to major pharmaceutical companies including Abbott, Lilly, Merck, Pfizer, Roche, Sanofi and Schering-Plough. These skills will enhance the activities of our clinical steering committee, which is instrumental in the design and conduct of Resverlogix's human clinical trials relating to its lead compound RVX-208," said Don McCaffrey, president and CEO.
Dr. Jan Johansson, senior vice president of medical affairs of Resverlogix, said, "Dr. Brewer's joining our Clinical Steering Committee further validates RVX-208's unique position in the critically important atherosclerosis market. Our highly differentiated mechanism in HDL biology, the raising of ApoA-I production and enhancement of RCT biomarkers, is seen by many as the most logical approach to harness the benefits of RCT and provide efficient reduction of atherosclerosis burden from coronary arteries. If our lead drug RVX-208 can facilitate this type of effect in high risk CVD patients in only 26 weeks it will be positioned as a new breakthrough treatment for millions of patients around the world."